JP2020532300A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532300A5
JP2020532300A5 JP2020512512A JP2020512512A JP2020532300A5 JP 2020532300 A5 JP2020532300 A5 JP 2020532300A5 JP 2020512512 A JP2020512512 A JP 2020512512A JP 2020512512 A JP2020512512 A JP 2020512512A JP 2020532300 A5 JP2020532300 A5 JP 2020532300A5
Authority
JP
Japan
Prior art keywords
peptide
item
cells
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020512512A
Other languages
English (en)
Japanese (ja)
Other versions
JP7385556B2 (ja
JP2020532300A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/049260 external-priority patent/WO2019046818A1/en
Publication of JP2020532300A publication Critical patent/JP2020532300A/ja
Publication of JP2020532300A5 publication Critical patent/JP2020532300A5/ja
Priority to JP2023192306A priority Critical patent/JP7644200B2/ja
Application granted granted Critical
Publication of JP7385556B2 publication Critical patent/JP7385556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020512512A 2017-09-01 2018-08-31 Bcma抗原に特異的な免疫原性ペプチドおよびその使用 Active JP7385556B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192306A JP7644200B2 (ja) 2017-09-01 2023-11-10 Bcma抗原に特異的な免疫原性ペプチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553669P 2017-09-01 2017-09-01
US62/553,669 2017-09-01
PCT/US2018/049260 WO2019046818A1 (en) 2017-09-01 2018-08-31 SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192306A Division JP7644200B2 (ja) 2017-09-01 2023-11-10 Bcma抗原に特異的な免疫原性ペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2020532300A JP2020532300A (ja) 2020-11-12
JP2020532300A5 true JP2020532300A5 (cg-RX-API-DMAC7.html) 2021-10-07
JP7385556B2 JP7385556B2 (ja) 2023-11-22

Family

ID=63678690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512512A Active JP7385556B2 (ja) 2017-09-01 2018-08-31 Bcma抗原に特異的な免疫原性ペプチドおよびその使用
JP2023192306A Active JP7644200B2 (ja) 2017-09-01 2023-11-10 Bcma抗原に特異的な免疫原性ペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192306A Active JP7644200B2 (ja) 2017-09-01 2023-11-10 Bcma抗原に特異的な免疫原性ペプチドおよびその使用

Country Status (8)

Country Link
US (2) US11517591B2 (cg-RX-API-DMAC7.html)
EP (1) EP3675897A1 (cg-RX-API-DMAC7.html)
JP (2) JP7385556B2 (cg-RX-API-DMAC7.html)
KR (1) KR102794702B1 (cg-RX-API-DMAC7.html)
CN (1) CN111655280B (cg-RX-API-DMAC7.html)
AU (2) AU2018326805B2 (cg-RX-API-DMAC7.html)
CA (1) CA3070468A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019046818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12215349B2 (en) * 2016-12-13 2025-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
EP0910409A4 (en) 1996-03-05 2003-03-19 Scripps Research Inst RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
EP1124568B1 (en) 1998-10-21 2007-08-22 Altor BioScience Corporation Polyspecific binding molecules and uses thereof
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
EP1092439A1 (en) 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
GB9930359D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
CN1312289A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人促性腺释放激素23和编码这种多肽的多核苷酸
NZ521629A (en) 2000-04-27 2004-05-28 Biogen Inc TACI as an anti-tumor agent
AU2001263114A1 (en) * 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1359937A4 (en) 2001-02-14 2004-07-28 Genzyme Corp MODIFIED PEPTIDE LIGANDS
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
KR20040019105A (ko) 2001-08-03 2004-03-04 제넨테크, 인크. TACIs 및 BR3 폴리펩티드 및 이의 용도
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20040072246A1 (en) 2001-09-11 2004-04-15 Roland Martin System and method for identifying t cell and other epitopes and the like
WO2005037995A2 (en) 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
EP1676132B1 (en) 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
WO2008143679A2 (en) * 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
ES2835200T3 (es) 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
JP6374392B2 (ja) * 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
PT2951202T (pt) 2013-01-29 2020-07-07 Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch Moléculas de ligação de alta avidez que reconhecem mage-a1
EP2968510B1 (en) 2013-03-14 2019-10-09 President and Fellows of Harvard College Nanoparticle-based compositions
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
US10767156B2 (en) 2013-10-24 2020-09-08 Yeda Research And Development Co., Ltd. Polynucleotides encoding BREX system polypeptides and methods of using same
EP3131927B8 (en) * 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3218404B1 (en) 2014-11-14 2021-01-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Human anti-thyroglobulin t cell receptors
BR112017014219A2 (en) 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
AU2016273213B2 (en) 2015-06-01 2019-03-14 Medigene Immunotherapies Gmbh T cell receptor library
US10228101B2 (en) 2015-07-01 2019-03-12 Mind Head Llc LED light fixtures and LED lamps that are used to replace Par 36 halogen lamps and incandescent well lights
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
NZ746700A (en) 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
PL3896091T3 (pl) * 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer

Similar Documents

Publication Publication Date Title
Palucka et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity
Tarhini et al. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma
Sommershof et al. Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma
Ashley et al. Bone marrow–generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
Chiang et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside
Berger et al. Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma
US20190275127A1 (en) Cancer vaccines and vaccination methods
Bianchi et al. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells
Schneider et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model
JP2005523277A (ja) 癌の治療
US11883490B2 (en) Induction of IL-12 using immunotherapy
Koski et al. Reengineering dendritic cell‐based anti‐cancer vaccines
Crittenden et al. Intratumoral immunotherapy: using the tumour against itself
JP2007523863A (ja) 予防又は治療目的のためのmhcクラスi拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
CN102281761A (zh) 用于增强免疫应答的方法和含有mTOR抑制剂的组合物
Wells et al. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity
WO2007149518A2 (en) Dna composition against tumor stromal antigen fap and methods of use thereof
Palucka et al. Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma
WO2018032501A1 (zh) 一种新的肿瘤特异性多肽及其应用
Szmania et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma
CN111655280A (zh) 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
Kim et al. Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells
US20120207775A1 (en) Immunogenic Epitopes as Targets for Universal Cancer Vaccines
JP6871432B2 (ja) Plk1タンパク質に対する抗原に特異的なt細胞の免疫反応を誘導するhla−a2亜型に特異的なplk1由来の抗原決定基
Stan et al. DNA vaccines against cancer